COVID-19: Federal & Non-Federal Funding Opportunities
To facilitate COVID-19 research projects, the OVPR has formed a team to identify funding opportunities and other programs to support this work. These opportunities will be shared with the research community on an ongoing basis.
Last updated on September 22, 2020
Jump to:
Federal
| SPONSOR | PROGRAM | FUNDING | DEADLINE |
|---|---|---|---|
| Department of Defense (DoD)
DARPA |
DARPA Broad Agency Announcements | Not Limited | Varies; 4/23/2020 for BTO |
| Department of Defense (DoD) | COVID-19 National Response Team | ||
| Department of Defense (DoD)
USAMRDC |
Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for COVID-19 Research | Vary with mechanism | Various |
| Department of Energy (DoE)
Argonne National Laboratory
|
Expedited, Rapid Access Call for COVID-19 Research | N/A | Ongoing |
| Department of Health and Human Services (HHS)
BARDA |
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) | Not limited | 10/31/2020 |
| Department of Health and Human Services (HHS)
BARDA |
2019 Novel Coronavirus Medical Countermeasure Partnership Opportunities | None specified | White Papers may be submitted on any day during open periods up to the following deadlines: 4/30/2020, 7/31/2020, 10/31/2020 |
| Department of Health and Human Services (HHS)
BARDA |
DRIVe EZ-BAA | Application date: ongoing | |
|
Department of Health and Human Services (HHS) CDC |
Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States | Vary with mechanism | 7/16/2023 |
| Department of State (DoS) | COVID-19 Small Grants Program | Maximum award amount: $100,000 | 9/30/2020 |
|
Department of State (DoS) E/GP |
Office of Global Partnerships: COVID-19 Private Sector Engagement & Partnership Fund | Anticipated awards of $50,000 to $1,000,000 | 5/30/2021 |
|
Department of State (DoS) U.S. Mission to India |
COVID-19 Small Grants Program | $100,000 | 9/30/2020 |
| Food and Drug Administration (FDA)
OGD |
PBPK Models of Oral Absorption to Simulate the Results of Bioequivalence Studies | Not specified | Not specified |
| National Institutes of Health (NIH)
AHRQ |
Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 | Not specified | None specified |
| National Institutes of Health (NIH)
NCATS |
Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs | Applications accepted on a rolling basis through 11/10/2020 | |
| National Institutes of Health (NIH)
NCATS |
Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need | Vary with mechanism | 7/10/2021 |
| National Institutes of Health (NIH)
NCATS |
Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) | Vary with mechanism | 10/17/2020 |
| National Institutes of Health (NIH)
NCATS |
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required) | Budgets limited to $3,000,000 direct costs/year for up to three years | 1/24/2021 |
| National Institutes of Health (NIH)
NCCIH, NIA, NIAAA
|
Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19) | Not specified | Applications accepted on a rolling basis through 10/6/2020 |
| National Institutes of Health (NIH)
NCI |
Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis | N/A -- allows existing resources to be redirected | For the duration of the present crisis |
| National Institutes of Health (NIH)
NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NIBIB, NCATS, NIAAA |
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional) | Up to level of parent award | Applications accepted on an ongoing basis through 3/25/2021 |
|
National Institutes of Health (NIH) NCI, NHGRI, NCCIH, NINDS, ORIP, NIMHD, NIA, NIDCR, NIAID, NIAMS, NIEHS, NCATS, NIDCD, NICHD, NIDDK, NHLBI |
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project | Up to $1,000,000 in direct costs for one year projects. | 7/13/2020, 11/12/2020, 3/12/2021, and 7/12/2021 |
| National Institutes of Health (NIH)
NHLBI |
(ROA): Host-targeting Therapies for COVID-19 | No specific limit | Applicants must first submit a Letter or Request. Stage 1 Letters of Request will be considered on a monthly bass starting (May 15, June 15, July 15, August 15). |
| National Institutes of Health (NIH)
NHLBI |
Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) | Up to level of parent award | Applications accepted on a rolling basis through 5/15/2020 |
|
National Institutes of Health (NIH) NIA |
NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) | Budgets are not limited; projects of up to 5 years | 7/1/2020; 8/3/2020; 9/1/2020; 10/1/2020; 11/2/2020; 12/1/2020; 1/4/2021; and 2/1/2021 |
| National Institutes of Health (NIH) NIAID |
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) | Application budgets should not exceed the annual amount of the current parent award; projects should not exceed two years. | Applications accepted on a rolling basis to 7/2/2021 |
| National Institutes of Health (NIH)
NIAID |
Administrative Supplement | Not Limited | 2/6/2020 (applications accepted through 2/6/2021) |
| National Institutes of Health (NIH)
NIAID |
2020 NIAID Omnibus Broad Agency Announcement (BAA) | Not Limited | 6/30/2021 |
| National Institutes of Health (NIH)
NIAID, NIGMS |
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) | Not limited | 2/6/2020 (applications accepted through 4/8/2020) |
| National Institutes of Health (NIH)
NIA, NIAAA, NICHD, NIDA, NIMH, NINDS, NINR, NIMHD, NCCIH |
Notice of Additional Due Date and Additional “Areas of Focus Especially of Interest” of PAR-19-373 and PAR-19-384, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" | Not limited | Application dates: 6/8/2020 and 3/17/2021 |
| National Institutes of Health (NIH)
NIA, NIMH
|
Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) | Not limited | 5/1/2021 |
| National Institutes of Health (NIH)
NIAAA |
Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA | Limited to no more than $100,000 direct costs per year for two, unless special permission is granted | 4/15/2021 |
| National Institutes of Health (NIH)
NIAID, NIA |
Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | Not limited | 5/13/2020; 9/13/2020; and others |
| National Institutes of Health (NIH)
NIAID |
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) | Application budgets are not limited but need to reflect the actual needs of the proposed project. | Applications accepted on a rolling basis through 7/8/2021 |
| National Institutes of Health (NIH)
NIAID |
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) | Up to level of parent award | 3/25/2021 |
| National Institutes of Health (NIH)
NIAID |
Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) | $4,050,000 | 6/29/2020 |
| National Institutes of Health (NIH)
NIAID |
Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed) | $275,000 (direct costs) | 9/9/2020 |
| National Institutes of Health (NIH)
NIAID |
Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2 | Not limited but prior approval required for applicants requesting $500,000 or more in direct costs in any year | 9/1/2021 |
| National Institutes of Health (NIH)
NIBIB |
Fast-Track Program for COVID-19 Test Development and Distribution | Various packages of project development work. | |
|
National Institutes of Health (NIH) NICHD |
Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract | Vary with mechanism | 7/16/2023 |
| National Institutes of Health (NIH)
NIDA |
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus | $100K direct costs/yr | 3/19/2020 (applications accepted through 3/31/2021) |
| National Institutes of Health (NIH)
NIDA
|
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus | No more than $100,000 unless strongly justified | 3/31/2021 |
| National Institutes of Health (NIH)
NIDCD
|
Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders | Vary with mechanism | Various application date on or after 10/5/2020 |
| National Institutes of Health (NIH)
NIDCR |
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR | Up to one year of support; requests should not exceed $150,000 in total direct costs without strong, compelling justification. | Application dates: 6/1/2020 and 11/2/2020 |
|
National Institutes of Health (NIH) NIDDK |
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) | Application budgets are limited to $250,000 in direct costs per year, for up to 3 years | 12/16/2020 |
| National Institutes of Health (NIH)
NIEHS |
Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) | Not specified | 5/4/2021 |
| National Institutes of Health (NIH)
NIGMS |
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 | Must reflect your needs | 3/5/2020 (applications accepted through 2/5/2021) |
| National Institutes of Health (NIH)
NIGMS |
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) | Up to level of parent award | 2/5/2021 |
|
National Institutes of Health (NIH) NIMHD |
Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) | Projects up to $500,000 direct costs annually, for 5 years. | 8/28/2020; 12/1/2020 |
|
National Institutes of Health (NIH) NIMH, NCCIH, SGMRO, ODP, NIDCD, OBSSR, NEI, NIDA, NIA, NIAAA, NICHD, NCATS, ORWH, NIDCR, NINR, NIMHD |
Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional) | Up to $750,000 direct costs per year, for 3 years | 8/20/2020, 12/2/2020, 3/2/2021 |
| National Institutes of Health (NIH)
NIMHD, NIA, NICHD, NIDCD, NIDCR, NIDA, NIEHS, NIMH, NINR, NCCIH |
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations | Up to no more than $250,000 in direct costs per year | Applications will be accepted on a rolling basis from 6/10/2020 through 12/15/2020 |
| National Institutes of Health (NIH)
NIMHD, NIA, NIMH |
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | No more than $125,000 in direct costs | 5/1/2021 |
| National Institutes of Health (NIH)
NIMHD, NIA, NIDA, NCI |
Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) | Budget not limited; projects up to 5 years | Standard NIH application dates, first date is 10/5/2020 |
| National Institutes of Health (NIH)
NIMH, NIA, NIAAA, NIMHD |
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus | Not specified | 4/15/2021 |
|
National Institutes of Health (NIH) NIMH, NEI, NIA, NIAAA, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NINR, NIMHD, NCCIH, NCATS |
Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 | Budgets are limited to no more than $200,000 direct costs | Applications will be accepted on a rolling basis through 12/15/2020 |
| National Institutes of Health (NIH)
NINDS |
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System | Budgets limited to $200,000 direct costs except in rare circumstances | Applications accepted on a rolling basis through 4/14/2021 |
| National Institutes of Health (NIH)
OBSSR, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, NICHD |
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences | Limited to no more than $100,000 direct costs per year unless strongly justified | Applications accepted on a rolling basis through 3/31/2021 |
| National Institutes of Health (NIH)
OD |
Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiatives | First due dates expected to be in July | |
| National Institutes of Health (NIH)
OD, NHLBI, NIAID, NIAMS, NICHD, NIDA, NIMHD, FIC, NCATS |
Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional) | Application budgets are limited to $500,000 in direct costs per year in the R61 phase and $1,000,000 in direct costs per year in the R33 phase. Applicants may request up to two years of support for the R61 phase, and up to two years of support for the R33 phase. | 9/30/2020 |
|
National Institutes of Health (NIH) OD, NHLBI, NIA, NIAAA, NICHD, NIDCD, NIDDK, NIDA, NIEHS, NIGMS, NINR, NIMHD, NLM, NCCIH |
Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed) | Up to $4 million in annual direct costs for 4 years | 9/30/2020 |
|
National Institutes of Health (NIH) OD, NIAAA, NIDCR, NIDDK, NIDA, NIGMS, NINR, NIMHD, NLM |
Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) | Budgets are not limited; projects of up to 3 years may be proposed | 9/30/2020 |
| National Institutes of Health (NIH)
OSC |
NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) | Budgets are not limited | 9/30/2020 |
| National Science Foundation (NSF) | Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) | Various | |
| National Science Foundation (NSF) | Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) | Various | |
|
National Science Foundation (NSF) BIO, ENG |
Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels) | Budgets not limited | The relevant programs in BIO/MCB and ENG/CBET all accept proposals without deadline. Proposals are reviewed as they are received. |
| National Science Foundation (NSF)
IIP |
Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 | Vary with mechanism | 12/3/2020 |
|
U.S. Department of Agriculture (USDA) NIFA |
Agriculture and Food Research Initiative - Foundational and Applied Science Program | Vary with grant type | 7/29/2021 |
| USG
PHEMCE |
CoronaWatch: COVID-19 MEETING REQUEST FOCUS | N/A |
Non-Federal
| SPONSOR | PROGRAM | FUNDING | DEADLINE |
|---|---|---|---|
| Amazon Web Services (AWS) | AWS Diagnostic Development Initiative (DDI) | Not specified | ongoing |
| American Association of Orthodontists Foundation | 2021 Award Proposals: Call for Proposals to Study COVID-19 Related Outcomes | Award maximums vary with program | 11/13/2020 |
| Cisco Research Center (CRC) | Pandemic/COVID19 Science, Technology and Social Impact | Not specified | Proposals are reviewed and funding decisions are made on a rolling basis. |
| COVID-19 Early Treatment Fund (CETF) | COVID-19 Early Treatment Fund (CETF) | Continuous submission | |
| COVID-19 HPC Consortium | The COVID-19 High Performance Computing (HPC) Consortium | Not specified | None specified |
| Cystic Fibrosis Foundation | SARS-CoV-2 and Cystic Fibrosis Research Award | Up to $125,000 per year (plus 12% for indirect costs) for up to two years. | Letter of Intent: 7/17/2020; Full application: 10/1/2020 |
| Draper Richards Kaplan Foundation | DRK COVID-19 Urgent Response Initiative (CURI) | The foundation anticipates funding for most projects to be in the $50k-100k range. | Continuous submission |
| Emergent Ventures | Fast Funding for COVID-19 Science | Up to $500,000 | None specified |
| Encephalitis Society | Encephalitis and Covid-19 - International Research Seed Funding | Up to £10,000 for projects of no more than 18 months duration | Proposals due by 8/31/2020 |
| Ferring Pharmaceuticals | Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health | EUR 25,000 | 10/31/2020 |
| Gilead Sciences | COVID-19 RFP Program: COMMIT™ (COvid-19 unMet MedIcal needs and associated research exTension) |
Up to $250,000 | Letters of intent accepted through to 8/3/2020 |
| COVID-19 Research Grants | Not specified | None specified | |
| Hopkins Population Center (HPC) | HPC Call for Lightning Pilot Applications to Population-Based Studies of COVID-19 | $5,000 - $10,000 | Rolling basis, reviews start 3/27/2020 |
| The Jacob and Valeria Langeloth Foundation | COVID-19 Rapid Response Fund (CRRF) | Not specified | Continuous submission |
| Mozilla.org | COVID-19 Solutions Fund | Up to $50,000 | Applications accepted on a rolling basis |
| Novartis US Foundation | Novartis COVID-19 Community Response Fund | $100,000 to $250,000 | None specified |
| Omidyar Network India | Rapid Response Funding for COVID-19 | Up to Rs. 2 crore (approx. $250,000) | Ongoing |
| Patient-Centered Outcomes Research Institute (PCORI) | PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects | $500,000 limit (direct and indirect costs)—higher amounts will be considered on a case-by-case basis | On a rolling basis |
| Patient-Centered Outcomes Research Institute (PCORI) | PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards | Up to $150,000 (direct and indirect costs) | Proposals considered on a rolling basis |
| Patient-Centered Outcomes Research Institute (PCORI) | PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards | $500,000 limit (direct and indirect costs)—higher amounts will be considered on a case-by-case basis | Proposals considered on a rolling basis |
| Patient-Centered Outcomes Research Institute (PCORI) | Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2020 | Investigators may request up to $2 million in direct costs for a feasibility phase up to 18 months in duration, with up to $20 million in direct costs for continuation to a full-scale study phase up to five years in duration. | Letter of Intent (LOI) Deadline: 9/29/2020; Full applications will be due Tuesday, 1/12/2021 |
| Robert Wood Johnson Foundation | Pioneering Ideas: Exploring the Future to Build a Culture of Health | The average Pioneer grant in 2019 was $315,031. However, there is not an explicit range for budget requests. Grant periods are flexible, though generally range from 1 to 3 years. | Open |
| TD Bank | 2020 TD Ready Challenge | One-time grants ranging from $350,000 CAD to $1 million CAD each (approximate equivalent of $260,000 USD to $745,000 USD) | |
| XPRIZE | XPRIZE Next-Gen Mask Challenge | Up to $500,000 | 10/22/2020 |